Biosimilars: New guns for the treatment of rheumatological patients?
The advent of biological therapies in 2000s has represented a real revolution in the treatment of patients affected by rheumatic diseases, but biosimilars represent nowadays a further revolution both from an economic point of view and for the accessibility to treatment for rheumatic patients. The ma...
Main Authors: | Daniela Marotto, Angela Ceribelli, Piercarlo Sarzi Puttini |
---|---|
Format: | Article |
Language: | English |
Published: |
Verduci Editore
2019-05-01
|
Series: | Beyond Rheumatology |
Subjects: | |
Online Access: | https://www.beyond-rheumatology.org/wp-content/uploads/sites/10/2022/05/br-1-1-3.pdf |
Similar Items
-
SAFETY AND CLINICAL EFFICACY IN BIOSIMILAR SUBSTITUTION
by: João Pedro Fernandes, et al.
Published: (2015-03-01) -
SAFETY AND CLINICAL EFFICACY IN BIOSIMILAR SUBSTITUTION
by: João Pedro Fernandes, et al.
Published: (2015-01-01) -
Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging
by: Liese Barbier, et al.
Published: (2022-03-01) -
A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability
by: Becciolini A, et al.
Published: (2017-06-01) -
The biosimilars journey: current status and ongoing challenges
by: Igor Age Kos, et al.
Published: (2018-10-01)